FLT3 inhibitor-induced neutrophilic dermatosis

Blood

Volumn 122, Issue 2, 2013, Pages 239-242

  Fathi, Amir T ^a   Le, Long ^a   Hasserjian, Robert P ^a   Sadrzadeh, Hossein ^a   Levis, Mark ^b   Chen, Yi Bin ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CD135 ANTIGEN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; LENALIDOMIDE; MITOXANTRONE; NUCLEOPHOSMIN; QUIZARTINIB; SORAFENIB; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; CELL DIFFERENTIATION; CHROMOSOME 7Q; CHROMOSOME DELETION; CORTICOSTEROID THERAPY; DRUG MEGADOSE; DRUG WITHDRAWAL; EVALUATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; INDUCTION CHEMOTHERAPY; LEUKOCYTE COUNT; LUNG NODULE; MALE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; MYELOBLAST; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NEUTROPHILIC DERMATOSIS; OSTEOSARCOMA; PANNICULITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEPSIS; SKIN BIOPSY; SKIN DISEASE; SKIN NODULE; STEM CELL TRANSPLANTATION; SUBCUTANEOUS NODULE; BIOPSY; CHEMICALLY INDUCED DISORDER; CHROMOSOME ABERRATION; DRUG ANTAGONISM; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; SKIN;

ADULT; BIOPSY; CHROMOSOME ABERRATIONS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; MALE; MIDDLE AGED; MUTATION; NEUTROPHIL INFILTRATION; PROTEIN KINASE INHIBITORS; SKIN; SKIN DISEASES;

EID: 84884484782     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-478172     Document Type: Article

References (27)

1. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10(12):1911-1918. (Pubitemid 27019637)
2. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, Linch DC; Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5): 2776-2784.
3. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752-1759.
4. Fathi AT, Chen YB. Treatment of FLT3-ITD acute myeloid leukemia. Am J Blood Res. 2011;1(2): 175-189.
5. Fathi AT, Chabner BA. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Oncologist. 2011;16(8):1162-1174.
6. Mizuki M, Schwable J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 2003;101(8):3164-3173. (Pubitemid 36858011)
7. Cortes JE, Perl AE, Dombret H, et al. Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients $ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts). 2012:Abstract 615.
8. Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMSlike tyrosine kinase 3 receptor (FLT3) and multitargeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010;28(28):4339-4345.
9. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117(12): 3294-3301.
10. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITDpositive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113(26):6567-6571.
11. Auclair D, Miller D, Yatsula V, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia. 2007;21(3):439-445.
12. Levis M, Allebach J, Tse KF, et al. A FLT3- targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002; 99(11):3885-3891. (Pubitemid 35332023)
13. Sexauer A, Perl A, Yang X, et al. Terminal myeloid differentiation in vivo is induced by F LT3 inhibition in FLT3/ITD AML. Blood. 2012;120(20): 4205-4214.
14. Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5(2):96-102. (Pubitemid 36553429)
15. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011;20(6): 810-817.
16. Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. Blood. 2004;103(5):1883-1890. (Pubitemid 38268987)
17. Radomska HS, Bassères DS, Zheng R, et al. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Exp Med. 2006;203(2):371-381. (Pubitemid 43290846)
18. Schepers H, Wierenga AT, van Gosliga D, Eggen BJ, Vellenga E, Schuringa JJ. Reintroduction of C/EBPalpha in leukemic CD341 stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood. 2007;110(4):1317-1325. (Pubitemid 47281431)
19. Helbling D, Mueller BU, Timchenko NA, et al. CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood. 2005;106(4):1369-1375. (Pubitemid 41129603)
20. Levis M, Tse KF, Smith BD, Garrett E, Small DA. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 2001;98(3):885-887.
21. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14): 2984-2992.
22. Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis,minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002;100(7): 2393-2398.
23. Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100(7):2387-2392.
24. Larson RS, Tallman MS. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol. 2003;16(3): 453-461.
25. Zhou J, Hu L, Cui Z, Jiang X, Wang G, Krissansen GW, Sun X. Interaction of SDF-1alpha and CXCR4 plays an important role in pulmonary cellular infiltration in differentiation syndrome. Int J Hematol. 2010;91(2):293-302.
26. Jacobi A, Thieme S, Lehmann R, et al. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts. Exp Hematol. 2010;38(3):180-190.
27. Rombouts EJ, Pavic B, Löwenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood. 2004;104(2):550-557. (Pubitemid 38900040)